nfkb family member sampler kit Search Results


95
Cell Signaling Technology Inc protein kinase mapk sampler kit
Protein Kinase Mapk Sampler Kit, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/protein kinase mapk sampler kit/product/Cell Signaling Technology Inc
Average 95 stars, based on 1 article reviews
protein kinase mapk sampler kit - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc protein mapk antibody sampler kit
Protein Mapk Antibody Sampler Kit, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/protein mapk antibody sampler kit/product/Cell Signaling Technology Inc
Average 96 stars, based on 1 article reviews
protein mapk antibody sampler kit - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

95
Cell Signaling Technology Inc anti phospho-jak2
Anti Phospho Jak2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti phospho-jak2/product/Cell Signaling Technology Inc
Average 95 stars, based on 1 article reviews
anti phospho-jak2 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

90
Cell Signaling Technology Inc anti-mapk
NVP-BEZ235 and Sorafenib inhibit the growth of renal cancer cell lines . A, 786-0 and Caki-1 cellular growth was monitored with colorimetric MTS assay after 48 hours of treatment with NVP-BEZ235 (NVP, 1 μM) or Sorafenib (Soraf, 10 μM) either alone or in combination, or DMSO (Control). Columns, mean cell viability relative to control of four independent experiments; bars, SD. *, P < 0.05, **, P < 0.01, #, P < 0.001 compared to control, or otherwise as specified by brackets. B, NVP-BEZ235 inhibits PI3K/mTOR pathway in renal cancer cells. 786-0 and Caki-1 cells were treated with increasing doses of NVP-BEZ235 or DMSO (Control) for 4 hours. Cells were subsequently lysed and lysates were examined for phospho-Akt (Ser 473), Akt, phospho-S6 (Ser 235/236) or S6 expression level by Western blot analysis. C, 786-0 and Caki-1 cells were treated with increasing doses of sorafenib or DMSO as a control for 4 hours. Cells were processed as under panel B and analyzed for <t>phospho-MAPK</t> and MAPK <t>(Thr202/Tyr204).</t> The illustrated blots are representative of three similar experiments.
Anti Mapk, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-mapk/product/Cell Signaling Technology Inc
Average 90 stars, based on 1 article reviews
anti-mapk - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

88
Cell Signaling Technology Inc peptides
NVP-BEZ235 and Sorafenib inhibit the growth of renal cancer cell lines . A, 786-0 and Caki-1 cellular growth was monitored with colorimetric MTS assay after 48 hours of treatment with NVP-BEZ235 (NVP, 1 μM) or Sorafenib (Soraf, 10 μM) either alone or in combination, or DMSO (Control). Columns, mean cell viability relative to control of four independent experiments; bars, SD. *, P < 0.05, **, P < 0.01, #, P < 0.001 compared to control, or otherwise as specified by brackets. B, NVP-BEZ235 inhibits PI3K/mTOR pathway in renal cancer cells. 786-0 and Caki-1 cells were treated with increasing doses of NVP-BEZ235 or DMSO (Control) for 4 hours. Cells were subsequently lysed and lysates were examined for phospho-Akt (Ser 473), Akt, phospho-S6 (Ser 235/236) or S6 expression level by Western blot analysis. C, 786-0 and Caki-1 cells were treated with increasing doses of sorafenib or DMSO as a control for 4 hours. Cells were processed as under panel B and analyzed for <t>phospho-MAPK</t> and MAPK <t>(Thr202/Tyr204).</t> The illustrated blots are representative of three similar experiments.
Peptides, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/peptides/product/Cell Signaling Technology Inc
Average 88 stars, based on 1 article reviews
peptides - by Bioz Stars, 2026-03
88/100 stars
  Buy from Supplier

91
Cell Signaling Technology Inc ser 807 811
NVP-BEZ235 and Sorafenib inhibit the growth of renal cancer cell lines . A, 786-0 and Caki-1 cellular growth was monitored with colorimetric MTS assay after 48 hours of treatment with NVP-BEZ235 (NVP, 1 μM) or Sorafenib (Soraf, 10 μM) either alone or in combination, or DMSO (Control). Columns, mean cell viability relative to control of four independent experiments; bars, SD. *, P < 0.05, **, P < 0.01, #, P < 0.001 compared to control, or otherwise as specified by brackets. B, NVP-BEZ235 inhibits PI3K/mTOR pathway in renal cancer cells. 786-0 and Caki-1 cells were treated with increasing doses of NVP-BEZ235 or DMSO (Control) for 4 hours. Cells were subsequently lysed and lysates were examined for phospho-Akt (Ser 473), Akt, phospho-S6 (Ser 235/236) or S6 expression level by Western blot analysis. C, 786-0 and Caki-1 cells were treated with increasing doses of sorafenib or DMSO as a control for 4 hours. Cells were processed as under panel B and analyzed for <t>phospho-MAPK</t> and MAPK <t>(Thr202/Tyr204).</t> The illustrated blots are representative of three similar experiments.
Ser 807 811, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ser 807 811/product/Cell Signaling Technology Inc
Average 91 stars, based on 1 article reviews
ser 807 811 - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier

90
Cell Signaling Technology Inc phosphorylated erbb-3 (tyr 1289
NVP-BEZ235 and Sorafenib inhibit the growth of renal cancer cell lines . A, 786-0 and Caki-1 cellular growth was monitored with colorimetric MTS assay after 48 hours of treatment with NVP-BEZ235 (NVP, 1 μM) or Sorafenib (Soraf, 10 μM) either alone or in combination, or DMSO (Control). Columns, mean cell viability relative to control of four independent experiments; bars, SD. *, P < 0.05, **, P < 0.01, #, P < 0.001 compared to control, or otherwise as specified by brackets. B, NVP-BEZ235 inhibits PI3K/mTOR pathway in renal cancer cells. 786-0 and Caki-1 cells were treated with increasing doses of NVP-BEZ235 or DMSO (Control) for 4 hours. Cells were subsequently lysed and lysates were examined for phospho-Akt (Ser 473), Akt, phospho-S6 (Ser 235/236) or S6 expression level by Western blot analysis. C, 786-0 and Caki-1 cells were treated with increasing doses of sorafenib or DMSO as a control for 4 hours. Cells were processed as under panel B and analyzed for <t>phospho-MAPK</t> and MAPK <t>(Thr202/Tyr204).</t> The illustrated blots are representative of three similar experiments.
Phosphorylated Erbb 3 (Tyr 1289, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phosphorylated erbb-3 (tyr 1289/product/Cell Signaling Technology Inc
Average 90 stars, based on 1 article reviews
phosphorylated erbb-3 (tyr 1289 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

93
Cell Signaling Technology Inc anti bcl xl
NVP-BEZ235 and Sorafenib inhibit the growth of renal cancer cell lines . A, 786-0 and Caki-1 cellular growth was monitored with colorimetric MTS assay after 48 hours of treatment with NVP-BEZ235 (NVP, 1 μM) or Sorafenib (Soraf, 10 μM) either alone or in combination, or DMSO (Control). Columns, mean cell viability relative to control of four independent experiments; bars, SD. *, P < 0.05, **, P < 0.01, #, P < 0.001 compared to control, or otherwise as specified by brackets. B, NVP-BEZ235 inhibits PI3K/mTOR pathway in renal cancer cells. 786-0 and Caki-1 cells were treated with increasing doses of NVP-BEZ235 or DMSO (Control) for 4 hours. Cells were subsequently lysed and lysates were examined for phospho-Akt (Ser 473), Akt, phospho-S6 (Ser 235/236) or S6 expression level by Western blot analysis. C, 786-0 and Caki-1 cells were treated with increasing doses of sorafenib or DMSO as a control for 4 hours. Cells were processed as under panel B and analyzed for <t>phospho-MAPK</t> and MAPK <t>(Thr202/Tyr204).</t> The illustrated blots are representative of three similar experiments.
Anti Bcl Xl, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti bcl xl/product/Cell Signaling Technology Inc
Average 93 stars, based on 1 article reviews
anti bcl xl - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

92
Cell Signaling Technology Inc iap family antibody sampler kit
NVP-BEZ235 and Sorafenib inhibit the growth of renal cancer cell lines . A, 786-0 and Caki-1 cellular growth was monitored with colorimetric MTS assay after 48 hours of treatment with NVP-BEZ235 (NVP, 1 μM) or Sorafenib (Soraf, 10 μM) either alone or in combination, or DMSO (Control). Columns, mean cell viability relative to control of four independent experiments; bars, SD. *, P < 0.05, **, P < 0.01, #, P < 0.001 compared to control, or otherwise as specified by brackets. B, NVP-BEZ235 inhibits PI3K/mTOR pathway in renal cancer cells. 786-0 and Caki-1 cells were treated with increasing doses of NVP-BEZ235 or DMSO (Control) for 4 hours. Cells were subsequently lysed and lysates were examined for phospho-Akt (Ser 473), Akt, phospho-S6 (Ser 235/236) or S6 expression level by Western blot analysis. C, 786-0 and Caki-1 cells were treated with increasing doses of sorafenib or DMSO as a control for 4 hours. Cells were processed as under panel B and analyzed for <t>phospho-MAPK</t> and MAPK <t>(Thr202/Tyr204).</t> The illustrated blots are representative of three similar experiments.
Iap Family Antibody Sampler Kit, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/iap family antibody sampler kit/product/Cell Signaling Technology Inc
Average 92 stars, based on 1 article reviews
iap family antibody sampler kit - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

90
Cell Signaling Technology Inc anti-bax (1:2000)
Overexpression of FtMt abrogates endothelial cell apoptosis after cerebral I/R. Western blot and densitometric analyses of ( A ) the ratio <t>of</t> <t>Bcl-2</t> to <t>Bax,</t> ( B ) the ratio of cleaved caspase-3 to procaspase-3 ( n = 4). The data are expressed relative to the mean value in the WT Con group ( n = 4). The results are presented as the mean ± SEM. ** p < 0.01.
Anti Bax (1:2000), supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-bax (1:2000)/product/Cell Signaling Technology Inc
Average 90 stars, based on 1 article reviews
anti-bax (1:2000) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Cell Signaling Technology Inc antibodies phospho-b-raf
Role of A2A adenosine receptor (A2AAR)-cAMP signaling in the mitogen-activated protein (MAP) kinase pathway. (A) Effect of A2AAR activation on Amadori-glycated albumin (AGA)-induced extracellular signal-regulated kinase (ERK) MAP kinase activation. Retinal microglial cells were treated with AGA (500 μg/mL) in the presence or absence of CGS21680 (20 and 40 μmol/L) for 4 hours. Phospho-ERK (p-ERK) and total ERK MAP kinase in cell lysates were determined using Western blot analysis. Data shown are the mean + SD of three experiments. (B, C) Effect of A2AAR activation on AGA-induced <t>C-Raf</t> (B) and B-Raf (C) activation. Retinal microglial cells were treated with AGA (500 μg/mL) in the presence or absence of CGS21680 (20 μmol/L) or 8-pCPT-cAMP (250 μmol/L) for the indicated times (0 to 60 minutes). Phospho-C-Raf (Ser338), <t>phospho-B-Raf,</t> total C-Raf, and B-Raf in the cell lysates were determined using Western blot analysis.
Antibodies Phospho B Raf, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies phospho-b-raf/product/Cell Signaling Technology Inc
Average 90 stars, based on 1 article reviews
antibodies phospho-b-raf - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

93
Cell Signaling Technology Inc nfκb antibody kit
Role of A2A adenosine receptor (A2AAR)-cAMP signaling in the mitogen-activated protein (MAP) kinase pathway. (A) Effect of A2AAR activation on Amadori-glycated albumin (AGA)-induced extracellular signal-regulated kinase (ERK) MAP kinase activation. Retinal microglial cells were treated with AGA (500 μg/mL) in the presence or absence of CGS21680 (20 and 40 μmol/L) for 4 hours. Phospho-ERK (p-ERK) and total ERK MAP kinase in cell lysates were determined using Western blot analysis. Data shown are the mean + SD of three experiments. (B, C) Effect of A2AAR activation on AGA-induced <t>C-Raf</t> (B) and B-Raf (C) activation. Retinal microglial cells were treated with AGA (500 μg/mL) in the presence or absence of CGS21680 (20 μmol/L) or 8-pCPT-cAMP (250 μmol/L) for the indicated times (0 to 60 minutes). Phospho-C-Raf (Ser338), <t>phospho-B-Raf,</t> total C-Raf, and B-Raf in the cell lysates were determined using Western blot analysis.
Nfκb Antibody Kit, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nfκb antibody kit/product/Cell Signaling Technology Inc
Average 93 stars, based on 1 article reviews
nfκb antibody kit - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

Image Search Results


NVP-BEZ235 and Sorafenib inhibit the growth of renal cancer cell lines . A, 786-0 and Caki-1 cellular growth was monitored with colorimetric MTS assay after 48 hours of treatment with NVP-BEZ235 (NVP, 1 μM) or Sorafenib (Soraf, 10 μM) either alone or in combination, or DMSO (Control). Columns, mean cell viability relative to control of four independent experiments; bars, SD. *, P < 0.05, **, P < 0.01, #, P < 0.001 compared to control, or otherwise as specified by brackets. B, NVP-BEZ235 inhibits PI3K/mTOR pathway in renal cancer cells. 786-0 and Caki-1 cells were treated with increasing doses of NVP-BEZ235 or DMSO (Control) for 4 hours. Cells were subsequently lysed and lysates were examined for phospho-Akt (Ser 473), Akt, phospho-S6 (Ser 235/236) or S6 expression level by Western blot analysis. C, 786-0 and Caki-1 cells were treated with increasing doses of sorafenib or DMSO as a control for 4 hours. Cells were processed as under panel B and analyzed for phospho-MAPK and MAPK (Thr202/Tyr204). The illustrated blots are representative of three similar experiments.

Journal: Molecular Cancer

Article Title: Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib

doi: 10.1186/1476-4598-10-90

Figure Lengend Snippet: NVP-BEZ235 and Sorafenib inhibit the growth of renal cancer cell lines . A, 786-0 and Caki-1 cellular growth was monitored with colorimetric MTS assay after 48 hours of treatment with NVP-BEZ235 (NVP, 1 μM) or Sorafenib (Soraf, 10 μM) either alone or in combination, or DMSO (Control). Columns, mean cell viability relative to control of four independent experiments; bars, SD. *, P < 0.05, **, P < 0.01, #, P < 0.001 compared to control, or otherwise as specified by brackets. B, NVP-BEZ235 inhibits PI3K/mTOR pathway in renal cancer cells. 786-0 and Caki-1 cells were treated with increasing doses of NVP-BEZ235 or DMSO (Control) for 4 hours. Cells were subsequently lysed and lysates were examined for phospho-Akt (Ser 473), Akt, phospho-S6 (Ser 235/236) or S6 expression level by Western blot analysis. C, 786-0 and Caki-1 cells were treated with increasing doses of sorafenib or DMSO as a control for 4 hours. Cells were processed as under panel B and analyzed for phospho-MAPK and MAPK (Thr202/Tyr204). The illustrated blots are representative of three similar experiments.

Article Snippet: Antibodies directed against phospho-Akt (S473), Akt, phospho-S6 ribosomal protein (Ser235/236), S6 ribosomal protein, phospho-MAPK (Thr202/Tyr204), MAPK, cleaved caspase-3 and actin were from Cell Signaling.

Techniques: MTS Assay, Expressing, Western Blot

Overexpression of FtMt abrogates endothelial cell apoptosis after cerebral I/R. Western blot and densitometric analyses of ( A ) the ratio of Bcl-2 to Bax, ( B ) the ratio of cleaved caspase-3 to procaspase-3 ( n = 4). The data are expressed relative to the mean value in the WT Con group ( n = 4). The results are presented as the mean ± SEM. ** p < 0.01.

Journal: Antioxidants

Article Title: Overexpression of Mitochondrial Ferritin Enhances Blood–Brain Barrier Integrity following Ischemic Stroke in Mice by Maintaining Iron Homeostasis in Endothelial Cells

doi: 10.3390/antiox11071257

Figure Lengend Snippet: Overexpression of FtMt abrogates endothelial cell apoptosis after cerebral I/R. Western blot and densitometric analyses of ( A ) the ratio of Bcl-2 to Bax, ( B ) the ratio of cleaved caspase-3 to procaspase-3 ( n = 4). The data are expressed relative to the mean value in the WT Con group ( n = 4). The results are presented as the mean ± SEM. ** p < 0.01.

Article Snippet: The following primary antibodies were used: anti-β-actin (1:10,000) and anti-transferrin receptor 1 (TfR1; 1:2000) were obtained from Sigma-Aldrich (St. Louis, MO, USA) (#A5441, #SAB4200398); anti-ferroportin1 (FPN1; 1:5000) and anti-divalent metal transporter 1 (DMT1±IRE; 1:5000) were obtained from Alpha Diagnostic International (San Antonio, TX, USA) (#MTP11-S, #NRAMP21-S, #NRAMP23-S); anti-4-hydroxynonenal (4-HNE), anti-mitochondrial ferritin (1:5000), anti-ferritin light chain (FtL; 1:10,000) and anti-ferritin heavy chain (FtH; 1:10,000) were obtained from Abcam (#ab46545, #ab66111, #ab109373, #ab183781); anti-caspase3 (1:5000), anti-Bcl-2 (1:2000) and anti-Bax (1:2000) were obtained from Cell Signaling Technology (Danvers, MA, USA) (#14220, #3498, #2772); anti-ZO-1 (1:2000), anti-occludin (1:2000) and anti-claudin-5 (1:2000) were obtained from Thermo Fisher (Waltham, MA, USA) (#PA5-85256, #40-4700, #34-1600).

Techniques: Over Expression, Western Blot

Role of A2A adenosine receptor (A2AAR)-cAMP signaling in the mitogen-activated protein (MAP) kinase pathway. (A) Effect of A2AAR activation on Amadori-glycated albumin (AGA)-induced extracellular signal-regulated kinase (ERK) MAP kinase activation. Retinal microglial cells were treated with AGA (500 μg/mL) in the presence or absence of CGS21680 (20 and 40 μmol/L) for 4 hours. Phospho-ERK (p-ERK) and total ERK MAP kinase in cell lysates were determined using Western blot analysis. Data shown are the mean + SD of three experiments. (B, C) Effect of A2AAR activation on AGA-induced C-Raf (B) and B-Raf (C) activation. Retinal microglial cells were treated with AGA (500 μg/mL) in the presence or absence of CGS21680 (20 μmol/L) or 8-pCPT-cAMP (250 μmol/L) for the indicated times (0 to 60 minutes). Phospho-C-Raf (Ser338), phospho-B-Raf, total C-Raf, and B-Raf in the cell lysates were determined using Western blot analysis.

Journal: The American Journal of Pathology

Article Title: A 2A Adenosine Receptor (A 2A AR) as a Therapeutic Target in Diabetic Retinopathy

doi: 10.1016/j.ajpath.2011.01.018

Figure Lengend Snippet: Role of A2A adenosine receptor (A2AAR)-cAMP signaling in the mitogen-activated protein (MAP) kinase pathway. (A) Effect of A2AAR activation on Amadori-glycated albumin (AGA)-induced extracellular signal-regulated kinase (ERK) MAP kinase activation. Retinal microglial cells were treated with AGA (500 μg/mL) in the presence or absence of CGS21680 (20 and 40 μmol/L) for 4 hours. Phospho-ERK (p-ERK) and total ERK MAP kinase in cell lysates were determined using Western blot analysis. Data shown are the mean + SD of three experiments. (B, C) Effect of A2AAR activation on AGA-induced C-Raf (B) and B-Raf (C) activation. Retinal microglial cells were treated with AGA (500 μg/mL) in the presence or absence of CGS21680 (20 μmol/L) or 8-pCPT-cAMP (250 μmol/L) for the indicated times (0 to 60 minutes). Phospho-C-Raf (Ser338), phospho-B-Raf, total C-Raf, and B-Raf in the cell lysates were determined using Western blot analysis.

Article Snippet: Antibodies for β-actin (Sigma), phospho-C-Raf (Ser338), phospho-B-Raf, C-Raf, B-Raf, phospho-ERK, and ERK mitogen-activated protein kinase (Cell Signaling Technology, Beverly, MA) were detected with a horseradish peroxidase-conjugated antibody and enhanced chemiluminescence (ECL) (Amersham BioSciences, Buckinghamshire, UK).

Techniques: Activation Assay, Western Blot